RP-A501 is being developed for Danon Disease, a rare genetic disorder characterized by thickening and weakening of the heart muscle, often resulting in heart failure, and for male patients, frequent death during adolescence or early adulthood. Rocket is the first company demonstrating safety and efficacy data in clinical studies for gene therapy targeting the heart.

An open-label, global Phase 2 pivotal clinical trial of RP-A501 for the treatment of Danon Disease has commenced. The trial is expected to enroll 12 male patients from the U.S. and EU. The trial will assess a co-primary endpoint consisting of LAMP2 protein expression and left ventricular (LV) mass reduction from baseline at 12 months.

Phase 2 Trial Sites

For more details about the RP-A501 for Danon Disease clinical trial, visit clinicaltrials.gov.

Frequently Asked Questions

The Natural History of a Disease is the typical progression of the disease over a person’s lifetime starting from its onset

Natural History studies are observational studies that gather comprehensive data on the course of the disease to gain a better understanding of its progression and impact on patients. Data captured may include information on the physical signs and symptoms patients experience, test results (for example blood tests or imaging), genetic information, and health-related quality of life, over a period of time. This information helps describe the disease course and identify important factors (e.g. demographic, genetic, and/or lab test results), that may contribute to better or worse disease outcomes.

Travel, accommodation, and food stipend would be provided. Study assessments are provided free of charge.

Natural History Studies are particularly important for rare diseases. Given the diversity of symptoms and the small size of the patient population, these studies are often the only opportunity for researchers and physicians to address significant knowledge gaps and obtain a robust understanding of the disease and patient experience.

Engaging in a Natural History Study offers numerous benefits to the community, such as:

  • Raising awareness in medical, academic and pharmaceutical sectors
  • Empowering rare disease patient communities with knowledge and support for advocating better healthcare policies and support services
  • Enhancing patient care with improved insights into disease progression, allowing for more personalized treatment plans and potentially earlier detection of complications
  • Contributing to advancements in healthcare

These studies provide various avenues to help inform and design clinical trials, such as:

  • Highlighting areas of unmet medical need
  • Understanding characteristics of the patient population to define a treatment benefit from a patient’s perspective.
  • Describing disease progression, enabling the identification of clinical outcome measures and biomarkers
  • Provide patient-centric data for health authorities such as the FDA, and other public health institutions to use in their review processes of investigational treatments.
Learn more about Rocket’s clinical trial for FA

Interested in learning more?
Visit our Patients & Caregivers page or email us at clinicaltrials@nullrocketpharma.com

View more details about the Phase 2 pivotal trial of RP-A501 and natural history study on clinicaltrials.gov.

To read our Expanded Access statement, click here.

Our Disease Focus

our focus hero

At Rocket, we are in pursuit of gene therapy cures for patients living with rare and devastating genetic diseases.

Our Pipeline

Rocket’s pipeline is comprised of first-in-class gene therapies that incorporate either AAV or LV approaches to gene therapy.

Cardiovascular

Danon disease is a rare genetic disorder that is characterized by severe and primarily hypertrophic cardiomyopathy. Skeletal muscle weakness and mild cognitive impairment are also common. The causative mutation has been identified in the gene encoding for lysosome-associated membrane protein (LAMP2), and in particular the LAMP2B version of the gene which is primarily expressed in heart, skeletal muscle and brain tissue. Affected cells cannot efficiently digest and recycle protein and other materials, leading to dysfunction in heart, muscle and brain cells. Male patients who don’t receive a heart transplant often pass away during adolescence or early adulthood from progressive heart failure.

RP-A501 is an investigational gene therapy consisting of a recombinant adeno-associated serotype 9 (AAV9) capsid containing a functional version of the human LAMP2B transgene (AAV9.LAMP2B) which is administered as a single intravenous (IV) infusion. RP-A501 has the potential to restore or stabilize cardiac function in patients with Danon disease.

Plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM), also known as ARVC or ARVD, is a devastating, inherited heart disease caused by mutations in the PKP2 gene and associated with life-threatening arrhythmias, cardiac structural abnormalities, and sudden cardiac death. Patients living with PKP2-ACM have an urgent unmet medical need, as current medical, implantable cardioverter defibrillator (ICD), and ablation therapies do not consistently prevent disease progression or arrhythmia recurrence, are associated with significant morbidity including inappropriate shocks and device and procedure-related complications, and do not address the underlying pathophysiology or genetic mutation.

RP-A601 is an investigational gene therapy consisting of a recombinant adeno-associated serotype rh74 (AAVrh74) capsid containing a functional version of the human PKP2 transgene (AAVrh74.PKP2) which is administered as a single intravenous (IV) infusion. RP-A601 has the potential to restore or stabilize cardiac function in patients with PKP2-ACM.

BAG3-associated dilated cardiomyopathy (BAG3-DCM) is a rare genetically driven form of heart failure caused by mutations in the BAG3 gene. The BAG3 protein is expressed predominantly in the heart, where it plays a role in multiple key cellular functions of the heart. Loss of BAG3 leads to an accumulation of misfolded and damaged proteins, which can impair the heart’s ability to contract, potentially leading to impaired cardiac function, heart failure, and even premature death.

RP-A701 is an investigational gene therapy consisting of a recombinant adeno-associated serotype rh74 (AAVrh74) capsid. Because BAG3 plays a role in multiple critical myocardial cell functions, we believe RP-A701 has the potential to restore or stabilize cardiac function in patients with BAG3-DCM.

Hematology

Leukocyte Adhesion Deficiency Type I (LAD-I) is a rare genetic disorder affecting the immune system and is caused by a defect in the ITGB2 gene, leading to a deficiency in CD18. Due to this deficiency, white blood cells are unable to leave the bloodstream to go to sites of infection or inflammation. As a result, patients with severe LAD-I can develop life-threatening infections which they are unable to fight. Without a successful bone marrow transplant, survival beyond childhood is rare.

RP-L201 is an investigational gene therapy containing autologous (patient-derived) hematopoietic stem cells (HSCs) that have been genetically modified with a lentiviral vector to contain a functional copy of the ITGB2 gene. RP-L201 has the potential to restore immune function, avoiding the onset of severe, recurrent life-threatening infections.

Fanconi Anemia (FA) is a rare genetic disorder affecting DNA repair and characterized by bone marrow failure (BMF), cancer predisposition, and congenital malformations. Approximately two-thirds of FA cases are caused by genetic defects in the FANCA gene, which results in the FA subtype known as FA Complementation Group A (FA-A). FA patients may develop severe bone marrow failure (very low blood counts), cancers of the blood or other cancers. Currently, donor-mediated bone marrow transplants are the most frequently utilized therapy for FA.

RP-L102 is an investigational gene therapy containing autologous (patient-derived) hematopoietic stem cells (HSCs) that have been genetically modified with a lentiviral vector to contain a functional copy of the FANCA gene. If given early in life, RP-L102 gene therapy has the potential to correct bone marrow cells and stabilize blood counts, avoiding progression to severe bone marrow failure.

Pyruvate Kinase Deficiency (PKD) is a rare genetic blood disorder characterized by excessive rupture of red blood cells (RBCs), resulting in frequent, chronic anemia that can lead to life-threatening complications for patients with the severe form of the disease. Patients with PKD frequently have anemia, chronic fatigue, yellowing of the skin and eyes (jaundice) and enlarged spleens.

RP-L301 is an investigational gene therapy containing autologous (patient-derived) hematopoietic stem cells (HSCs) that have been genetically modified with a lentiviral vector to contain a functional copy of the PKLR gene. RP-L301 has the potential to correct multiple disease elements associated with PKD.

Wave 2 Progams

We are using our successful disease-first approach to advance multiple undisclosed candidates to potential clinical development.

Learn more about Rocket's clinical trials for these disease areas
Scroll to Top